Company Snapshot

Investment Thesis

Revvity (formerly part of PerkinElmer) focuses on diagnostics, life science reagents, and contract research solutions. High-growth prenatal screening, newborn testing, and specialty reagents support recurring revenue.

  • Diagnostics: Genetic screening and infectious disease assays
  • Life Sciences: Reagents, imaging, automation for pharma and biotech
  • Services: CDMO and lab services provide resilience

Strategic Mix

Diagnostics Newborn screening, reproductive health
Life Sciences Reagents, imaging
Services CDMO, informatics
Geography Americas, EMEA, APAC

Mix mirrors Revvity's diagnostics vs. life science services portfolio.

Recent Performance

MTD TBD
QTD TBD
YTD TBD
5Y TBD

Maxim is cueing up returns data for this security. Once the nightly supported.csv job runs, these metrics will auto-populate.

Strategic Insights

Precision Diagnostics

NIPT and newborn screening expand internationally.

Lab Services

Contract testing smooths revenue vs. equipment cycles.

Portfolio Focus

Divesting commodity assets funds higher-growth platforms.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...